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The practical realization of disease modulation by
catalytic degradation of a therapeutic target protein
suffers from the difficulty to identify candidate prote-
ases, or to engineer their specificity. We identified 23
measurable, specific, and new protease activities us-
ing combinatorial screening of 27 human proteases
against 24 therapeutic protein targets. We investi-
gate the cleavage of monocyte chemoattractant pro-
tein 1, interleukin-6 (IL-6), and IL-13 by matrix metal-
loproteinases (MMPs) and serine proteases, and
demonstrate that cleavage of IL-13 leads to potent
inhibition of its biological activity in vitro. MMP-8
degraded human IL-13 most efficiently in vitro and
ex vivo in human IL-13 transgenic mouse bronchoal-
veolar lavage. Hence, MMP-8 is a therapeutic prote-
ase lead against IL-13 for inflammatory conditions
whereby reported genetic and genomics data sug-
gest an involvement of MMP-8. This work describes
the first exploitation of human enzyme promiscuity
for therapeutic applications, and reveals both start-
ing points for protease-based therapies and poten-
tial new regulatory networks in inflammatory disease.
INTRODUCTION
Enzymes for a wide variety of applications, ranging from indus-
trial biocatalysis to nutritional and medical use, are needed but
currently not available. De novo design of proteins is difficult
(Hilvert, 2013), and harvesting metagenomic biodiversity has
low hit rates and is therefore expensive (Lorenz and Eck, 2005;
Uchiyama and Miyazaki, 2009). Enzyme promiscuity (Copley,
2015; Jensen, 1976; Khersonsky and Tawfik, 2010; O’Brien
and Herschlag, 1999; Van Loo et al., 2010) describes the ability
of enzymes to recognize substrates other than their native1442 Chemistry & Biology 22, 1442–1452, November 19, 2015 ª2015ones, or catalyze related but different chemical reactions.
Instead of designing or identifying entirely ‘‘new’’ enzymes,
such side activities have the potential to be a source of new ac-
tivities when promiscuous enzymes are used in a novel context.
This phenomenon has been exploited for the adaptation of exist-
ing enzymes to organic synthesis and biotechnology (Bornsche-
uer and Kazlauskas, 2004; Nobeli et al., 2009). However, enzyme
promiscuity might also be used to find starting points for human
therapy. This is exemplified by our present work in which we
identify therapeutically relevant protease activities that are suit-
able starting points for further drug discovery by characterizing
the reactions of well-known human proteases with therapeuti-
cally relevant targets, an approach that would give insights into
promiscuous proteolytic processing activities.
A number of physiological and cellular processes, as diverse
as hemostasis (Furie and Furie, 1988), complement activation
(Sim and Tsiftsoglou, 2004), and apoptosis (Stennicke and Sal-
vesen, 2000), are regulated by proteolytic processing, with spe-
cific proteases recognizing specific amino acid sequences and
catalyzing the hydrolysis of specific peptide bonds in their
target substrates. Proteases are distinguished by their sub-
strate specificity, so re-engineering of the substrate spectrum
or creating new specificities in laboratory evolution experiments
is necessary to tailor proteases to a given target substrate and
potential therapeutic applications (Li et al., 2013; Pogson et al.,
2009).
Proteases directed at specific target substrates might be de-
ployed therapeutically with an objective similar to that of neu-
tralizing monoclonal antibodies. However, unlike antibodies,
therapeutic proteases would offer a number of unique advan-
tages. Antibodies neutralize their targets stoichiometrically,
requiring high and potentially unsafe doses to quantitatively
neutralize abundant antigens. This stoichiometric action leaves
antibodies susceptible to antigen ‘‘sinks,’’ which reduce their
pharmacokinetics and subsequent efficacy (Keating et al.,
2002). In contrast, proteases inactivate their targets catalytically
and irreversibly. As a result of multiple catalytic turnover, one
protease molecule neutralizes several target molecules, poten-
tially resulting in lower and more convenient dosing, leading toElsevier Ltd All rights reserved
cost savings and fewer side effects. While proteases can effi-
ciently remove a protein target, therapeutic antibodies only
neutralize their specific target, but through their specific and
high-affinity binding will act as carriers of their target in circula-
tion, and can thereby prolong the pharmacological effects of
their antigen (Finkelman et al., 1993). Finally, the high affinity of
antibodies, while required for their function, can inhibit tissue
penetration (Adams et al., 2001; Beckman et al., 2007). The lower
affinity of proteases for their substrates and their catalytic activity
may help them remain therapeutic, even in the presence of anti-
gen sinks, and achieve higher tissue penetration.
To date, clinical applications of proteases have been exclu-
sively based on the specificity of natural proteases to catalyze
the hydrolysis of their native substrates to therapeutic effect
(Craik et al., 2011), in many instances as enzyme replacement
therapy such as for many of the coagulation factors. Although
it would be very attractive to widen the therapeutic scope of
proteases, the requirements in terms of activity and specificity
are demanding. Multiple approaches in directed protein evolu-
tion and rational structural redesign have been used to repro-
gram the specificity of existing proteases (Gordon et al., 2012;
O’Loughlin et al., 2006; Perona and Craik, 1995, 1997; Varadar-
ajan et al., 2008, 2009; Yi et al., 2013). It should be noted that in
each of these efforts an original activity was altered, rather than
created de novo. Indeed, no de novo protein design approach
has been successful in the creation of an entirely new protein
capable of cleaving unactivated peptide bonds, despite the suc-
cess of tools such as Rosetta in the design of catalysts for less
demanding reactions (Hilvert, 2013). These observations high-
light the crucial importance of identifying a starting point, such
as a protease lead with some detectable activity against a ther-
apeutic target of interest, for further tailoring.
We now set out to identify therapeutically relevant protease
activities that are suitable starting points for further drug discov-
ery by characterizing the reactions of well-known human prote-
ases with therapeutically relevant targets, an approach that
would give insights into promiscuous proteolytic processing ac-
tivities. Several proteases showed efficient and site-specific hy-
drolysis of targets other than their native substrates. We went
beyond mere demonstration of proteolytic in vitro cleavage by
additionally validating the therapeutic utility of this activity in
cell-based assays that showed substrate neutralization. While
the cleavage of interleukin-6 (IL-6) and the monocyte chemoat-
tractant protein 1 (MCP-1/CCL-2) had no significant effect on
their biological activity, the matrix metalloproteinase 8 (MMP-8)
showed neutralizing hydrolysis of the pro-inflammatory cytokine
IL-13. Since IL-13 is a key therapeutic target in several inflamma-
tory conditions (Wynn, 2003), we further characterized MMP-8
and other MMPs for additional properties that are required with
a view to future use as a therapeutic candidate.
Finally, we demonstrate that MMP-8 can quantitatively neu-
tralize human IL-13 ex vivo in bronchoalveolar lavage (BAL), rep-
resenting themajor constituents of the lung interstitial tissue, and
thereby constitutes a relevant model of inhaled therapy. With
such promiscuous starting points capable of site-specific hydro-
lysis of targets other than their native substrates, the scope of
protease pharmacology can be further improved by protein en-
gineering to increase selectivity, escape endogenous inhibitors,
and improve in vivo exposure.Chemistry & Biology 22, 1442–145RESULTS
A Matrix for Testing 27 Proteases against 24 Targets
To identify novel promiscuous proteolytic reactions with thera-
peutic potential, we created a panel of 27 proteases with fea-
tures that made them suitable for further engineering and
development: preferably of human origin (to limit the potential
for immunogenicity), well-studied, commercially available, and
with a three-dimensional structure solved. This panel was
tested against 24 proteins chosen from validated and potential
targets for therapeutic antagonists. Proteolysis reactions were
classified as either site specific when the target was cleaved
into only two distinct fragments, efficient when an enzyme
cleaved more than half of the target within 24 hr, or both. We
preferred proteases acting on a single site in their target sub-
strates to allow for the potential to identify the exact site of
the hydrolysis by mass spectrometry. This identification would
unambiguously assign any alteration or neutralization of target
function to the cleavage of one specific peptide bond, and
would ensure that future efforts to engineer the protease spec-
ificity and activity will be directed toward a therapeutically rele-
vant epitope.
The matrix, compiling the results of all the proteolytic reac-
tions tested, is shown in Figure 1. For the majority of protease/
substrate combinations (60%), no substrate hydrolysis was
observed. For those where there was evidence of substrate hy-
drolysis, most could be characterized as slow or non-specific
cleavages, or both. Approximately 5% of combinations resulted
in hits, i.e. reactions that could be described as site specific and
that occurred with a measurable rate, producing detectable
cleavage products within 24 hr.
Hits for the cleavage of IL-13 were MMP-1, MMP-8, and
MMP-12. The site of proteolysis was identified by mass spec-
trometry with the P1 residue being Lys75 for the cleavage by
MMP-8 (Table S1). Samples of IL-13 digested with the most
efficient protease as observed in the matrix, MMP-8, were
further tested in a TF1 cell-proliferation bioassay. Product anal-
ysis by SDS-PAGE showed that IL-13 had undergone essen-
tially complete digestion (R98%) via the action of MMP-8
(Figure 2). The bioassay (Figure 2) showed that the proteolyzed
sample of IL-13 had an approximately 50- to 100-fold increase
in its half maximal effective concentration (EC50). This is consis-
tent with the proteolysis of IL-13 being completely neutralizing,
i.e. cleaved IL-13 having no ability to stimulate TF1 prolifera-
tion, and the residual activity observed for this sample being
attributable to the small proportion of undigested IL-13. The
site of hydrolysis is located near the beginning of the loop be-
tween the helices C and D, for which nuclear magnetic reso-
nance (NMR) studies are indicative of a flexible region, and
shortly after the last of the four cysteine residues forming two
disulfide bonds in the molecule (Eisenmesser et al., 2001;
Moy et al., 2001). Thus the cleavage severs the covalent
connection between receptor binding, functional epitopes of
IL-13 (D helix [LaPorte et al., 2008]), and the rest of the mole-
cule. This structural information and the bioassay data show
that MMP-8 hydrolysis of IL-13 is neutralizing.
IL-6 was cleaved specifically by kallikrein-7 (KLK-7) after
Leu19, as determined by mass spectrometry (Table S1). A TF1
proliferation bioassay of hydrolyzed IL-6 by KLK-7 showed2, November 19, 2015 ª2015 Elsevier Ltd All rights reserved 1443
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Figure 1. A Matrix for Empirical Exploration of Promiscuous Proteolysis Reactions
(A) Digestions were set up with a target/enzyme ratio of 20:1 for 3 and 24 hr, at 37C, and analyzed by SDS-PAGE.
(B) The site of cleavage, when specific (i.e. target cleaved into two fragments), was determined by MALDI (example: cleavage of IL-13 by MMP-8).
(C) Thematrix describes a qualitative assessment of each proteolytic combination as revealed by SDS-PAGE. Not cleaved: no observed proteolysis. Site-specific
cleavage: two proteolytic fragments observed by SDS-PAGE, indicating rapid (observable after 3 hr) and site-specific proteolysis. Non-specific cleavage: the
appearance of multiple bands on SDS-PAGE is observed. Low activity: proteolysis may be site specific, but products are less than 50% of starting material after
24 hr. Low activity and non-specific: non-specific proteolysis accounts for less than 50% of starting material after 24 hr.that, although the sample appeared to be R98% proteolyzed
(Figure 2), the EC50 for this sample was not increased, and that
removal of IL-6 N-terminal residues had no effect on IL-6 activity.
This observation can be explained by the structural disorder of
these residues in solution (Xu et al., 1997), which are part of a
portion of IL-6 that is not visible in crystal and co-crystal struc-
tures of this cytokine and are not part of the binding surface
(Boulanger et al., 2003; Somers et al., 1997).1444 Chemistry & Biology 22, 1442–1452, November 19, 2015 ª2015MCP-1 was cleaved by MMP-1, -2, -3, -7 -8, and elastase-2,
resulting in a small but clear shift in its apparent size, and the
digestion appeared to be complete. The P1 site for this reaction
was shown by mass spectrometry analysis of the reaction
products to be Ala4 (Table S1). This cleavage had already
been reported in the literature for MMP-1, -3, and -8 (Angus
McQuibban et al., 2002). A fluorescent imaging plate reader
(FLIPR) Ca2+ release bioassay for processed MCP-1 showedElsevier Ltd All rights reserved
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Figure 2. Quantification of Protease Activity by In Vitro and Biological Assays
Silver-stained SDS-PAGE and bioassays of proteolyzed IL-13, IL-6, and MCP-1.
(A) SDS-PAGE gels of proteolysis reactions are shown for three substrate/protease pairs. Lane 1, protein substrate control; lane 2, proteolysis reaction mix
stopped by addition of appropriate inhibitor; lane 3, proteolysis mix control whereby inhibitors and protein substrate were added before the protease; lane 4,
protease and inhibitor control.
(B) TF-1 proliferation assays for IL-13 and IL-6 show stimulation of the tritiated thymidine incorporation by TF-1 cells in a dose-dependent manner, as shown by
increase in counts per minute (CPM). An FLIPR assay for MCP-1 shows calcium release through binding to a calcium-sensitive fluorescent dye. Upon MCP-1-
receptor binding, intracellular calcium is released, thereby increasing fluorescence intensity. Four samples corresponding to lanes 1, 2, 3, and 4 of the SDS-PAGE
gels were tested, where P is the protease and I the appropriate inhibitor. Data shown are means ± SEM in duplicate and measured at the same time.that, although the sample appeared to be R98% proteolyzed
by the action of MMP-8, the EC50 for this sample was in-
creased by only a factor of three, and the final amount of cleav-
age was lower (Figure 2). Gong and Clark-Lewis (1995) have
shown, via N-terminally truncated MCP-1 analogs, that an
MCP-1 variant beginning with Ile5 was indeed shown to retain
some activity, but may not be as competent as wild-type for
signaling (Gong and Clark-Lewis, 1995). This behavior of
MCP-1 truncation suggests that the activity measured for
proteolyzed MCP-1 is in fact due to the truncated species
rather than the undigested material, and that the proteolysis
of MCP-1 by MMP-8 is not neutralizing.
TWEAK was specifically cleaved by trypsin, elastase-2, and
matriptase. Cleavage by trypsin and matriptase resulted in
cleavage of only a few residues at the N or C terminus (as
observed for IL-6 and MCP-1), making it likely that no inhib-
itory effect was brought about by the cleavage, and this
was not investigated further. Cleavage by elastase-2 was
found to be at Ala105 by mass spectrometry (Table S1). How-
ever, elastase-2 is, as shown in the matrix, a non-specific
protease with many off-targets that is unlikely as a potential
therapeutic protease due to this lack of specificity. Granulo-
cyte-macrophage colony-stimulating factor was cleaved site
specifically by MMP-12, and placental growth factor was
cleaved by ten different proteases. However, both targets
showed the removal of only a few residues, making a signif-
icant loss in bioactivity unlikely, and were not investigated
further.Chemistry & Biology 22, 1442–145IL-13 Is Cleaved Efficiently by a Panel of MMPs
IL-13 is a TH2 cytokine that directsmanyof the important features
of airway inflammation and remodeling in patients with allergic
asthma, and is a key target in the treatment of this disease.
MMPs are a family of Zn2+-dependentmetalloproteinaseswhose
primary function is to degrade a number of extracellular matrix
(ECM) proteins, in particular collagen, gelatin, fibronectin, fibrin,
and laminin. In humans, MMPs consist of 23 distinct mem-
bers. They are multidomain enzymes composed of a C-terminal
domain (called the hemopexin-like domain) connected to the cat-
alytic domain via an extended linker (called the hinge). The hemo-
pexin-like domain is believed to be involved in substrate recogni-
tion and substrate specificity, while the catalytic domain contains
the active site responsible for enzymatic substrate proteolysis,
and can be expressed in an active form (Visse and Nagase,
2003). In the matrix, catalytic domains of ten MMPs were tested
(Figure 1), ofwhich threewereable tocleave IL-13site specifically
and efficiently, and were neutralizing. We aimed at testing every
high-quality MMP catalytic domain commercially available for
IL-13 cleavage. Proteolysis reactions of IL-13 were repeated
with this new panel of MMPs (including MMP-9, -10, and -20,
not tested previously) to identify the most efficient proteases.
Only MMP-2 and -9 were unable to cleave IL-13. Every other
MMP tested successfully cleaved IL-13, as shown by the
appearance of two degradation products (F1 and F2) and/or
the concomitant disappearance of intact IL-13 (Figure 3).
MMP-1, -7, -8, -12, -13, and -20 were able to hydrolyzeR50%
of the protein within 24 hr. MMP-8 showed the most rapid2, November 19, 2015 ª2015 Elsevier Ltd All rights reserved 1445
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Figure 3. Hydrolysis of IL-13 by the Catalytic Domains of MMPs
5 mM IL-13 was incubated with 250 nMMMP for (A) 3 hr and (B) 24 hr, at 37C in
PBS, 1 mMCaCl2, 20 mMZnCl2 (pH 7.4), and reaction products were analyzed
by SDS-PAGE. I is intact IL-13 and F1 and F2 are the main products generated
by proteolysis.
Table 1. Cleavage of IL-13 and Stability Data of MMPs
Cleavage of IL-13
in 24 hra (%)
Activity
Half-Lifeb (hr)
Stability
Groupc
MMP-1 R50 210 high
MMP-2 0 2 low
MMP-3mut %50 230 high
MMP-7 R50 49 medium
MMP-8 R50 3 low
MMP-9 0 27 medium
MMP-10mut %50 65 medium
MMP-12 R50 3.5 low
MMP-12mut R50 47 medium
MMP-13 R50 4.6 low
MMP-20 R50 165 high
aCleavage of IL-13 was assessed by SDS-PAGE semi-quantitatively for
all MMP catalytic domains (as in Figure 1A).
bHalf-life of MMPs was measured at 37C in assay buffer by measuring
the protease residual activity on the substrate FS-6 (generating a FRET
signal).
cBased on the half-life, MMPs were classified into three groups of high,
low, and medium stability.cleavage with R95% of IL-13 cleaved within 3 hr, followed by
MMP-12 and -20. MMP-1, -7, and -13 showed lower activity
as intact IL-13 was still visible. The specificity for sequences tar-
geted for cleavage within IL-13 also varied among MMPs: MMP-
1, -8, -12, and -20 cleaved IL-13 into the same two fragments,
but differences in the intensity of the degradation products F1
and F2 were observed, suggesting that these by-products
were further degraded at different speeds, as a result of MMPs
differences in specificity.
Stability of the MMP Catalytic Domains
One limitation in the use of proteases in industrial applications is
that aqueous solutions of proteases may undergo autolysis, i.e.
the proteases may be self-hydrolyzing. Wild-type MMPsmay be
suboptimal in this regard; autolysis is known to be intrinsic to
several MMPs (Bertini et al., 2004; Bhaskaran et al., 2007; Kohno
et al., 2006; Ra et al., 2009). To test the relative stability of our
panel of proteases, we incubated them in assay buffer for
several days, and the remaining protease activity was measured
at regular intervals using the fluorescence resonance energy
transfer (FRET) substrate FS-6 (Neumann et al., 2004). The
MMP catalytic domains were classified into three groups based
on retention of their initial activity (Table 1): the first group,
composed of MMP-1, MMP-3mut, and MMP-20 all retained
more than 50% of their original activity, making them the most
stable MMPs in this study. The second group, comprising
MMP-7, MMP-9, MMP-10mut, and MMP-12mut, only retained1446 Chemistry & Biology 22, 1442–1452, November 19, 2015 ª20155%–25% of their original activity after 6 days, with half-lives in
the range of 1–3 days. The third group, composed of MMP-2,
MMP-8, MMP-12, and MMP-13, was the least stable with half-
lives of 2–5 hr.
MMP-1, -8, -12, and -20 Are Promising Candidates for
Use in Therapy
The two most active proteases, MMP-8 and MMP-12 (which
are also part of the least stable group) and the two most stable
proteases, MMP-1 and MMP-20 (which show medium and
high activity toward the IL-13 substrate), were further character-
ized. kcat/KM of these four MMPs for the hydrolysis of the MMP
generic substrate FS-6 were measured, showing that FS-6 is a
good substrate for all four MMPs, with kcat/KM falling between
33 104–105 M1 s1 (Table 2), in agreement with previous mea-
surements (Fulcher and Van Doren, 2011; Neumann et al., 2004).
kcat/KM values for the cleavage of IL-13 (Table 2) were found to
be in the range 200–1,200 M1 s1, and correlated well with
product analysis by SDS-PAGE, withMMP-8 being themost effi-
cient MMP for IL-13 cleavage, followed by MMP-12, -20 and -1,
in decreasing order of efficiency.
Since all MMPs appeared to cleave IL-13 at the same site in
the loop between helices C and D, as suggested by the presence
of the degradation products F1 and F2 (Figure 3), the effect of the
cleavage on IL-13 activity was tested in a TF1 proliferation assay
as described for MMP-8. All MMPs cleaved IL-13 in a neutral-
izing fashion (data not shown).
Our measurements of IL-13 hydrolysis showed that the effi-
ciency of the cleavage by MMPs was lower compared with
cleavage of its preferred substrate (e.g. collagen) (Gioia et al.,
2002). However, the cleavage might not be biologically relevant
in vivo, where IL-13 concentrations are as low as 50–200 pg/ml in
the lung of asthmatic mice (May et al., 2012). Also, it was impor-
tant to test the ability of MMPs to cleave endogenous, glycosy-
lated IL-13. To test the activity on human IL-13 at relevantElsevier Ltd All rights reserved
Table 2. Kinetic Data of MMPs
kcat/KM (M
1 s1) Ki
c (pM)
FS-6a IL-13b TIMP-1 TIMP-2 TIMP-3
MMP-1 6.3 ± 0.1 3 104 185 ± 14 ND ND ND
MMP-8 2.65 ± 0.03 3 105 1,140 ± 210 11,400 ± 800 1,850 ± 130 1,190 ± 110
MMP-12 3.6 ± 0.04 3 104 670 ± 290 ND ND ND
MMP-20 1.7 ± 0.03 3 105 270 ± 30 158 ± 8 286 ± 35 1,734 ± 23
ND, not determined.
akcat/KM for the FS-6 substrate were determined at room temperature from a linear fit of the measured velocity data to the equation V = (kcat/KM)[E][S].
bkcat/KM for IL-13 was calculated from the half-life, using a form of the integrated rate equation kcat/KM = ln2/(t1/2.[E]).
cKi was calculated by plotting initial rates of hydrolysis of the substrate FS-6 at different inhibitor concentrations (0–100 nM), and fitted to the equation
v0/vi = 1 + [I0]/Ki(app).physiological concentrations, we incubated MMPs with mice
knockin/knockout BAL samples containing endogenous human
IL-13, but notmouse IL-13, and levels of IL-13weremeasured by
sandwich ELISA (Figure 4). MMP-8 and MMP-20 were the most
efficient catalysts for cleavage of IL-13 in BAL samples, as about
85% of the cytokine was hydrolyzed, whereas only 40% and
15% of IL-13 were hydrolyzed by MMP-1 and MMP-12, respec-
tively. Despite being highly stable, MMP-1 did not cleave even
half of the protein substrate within the time frame of the experi-
ment. MMP-12 was the least efficient as most IL-13 remained
intact; however, when incubated in vitro with recombinant IL-
13, MMP-12 completely hydrolyzed the sample within 24 hr.
Those discrepancies between hydrolysis of IL-13 in buffer and
BAL samples might be due to components of the complex
mixture obtained from lung lavage, which could include inhibi-
tors that negatively modulate the activity of MMP-1 and MMP-
12 in BAL samples.
MMPs are tightly regulated at multiple levels, including gene
transcription, activation of the latent enzyme by proteolysis,
and inactivation by specific inhibitors. An important class of
endogenous MMP inhibitors is the tissue inhibitors of metallo-
proteinases (TIMPs), which play a critical role in ECM remodeling
by controlling the activity of MMPs (Visse and Nagase, 2003). We
determined the inhibition of the two MMPs, MMP-8 and MMP-
20, that were demonstrated to efficiently cleave human IL-13 in
BAL samples. The comparison of Ki values (Table 2) shows
thatMMP-8 is less sensitive to TIMP-1with an inhibition constant
ten times higher than TIMP-2 and -3. MMP-20 is strongly in-
hibited by all TIMPs with inhibition constants in the subnano-
molar range. This is consistent with MMP-20 broad substrate
specificity, allowing access to inhibitor and promiscuous sub-
strate alike.
MMP-8 Is Suppressed in Atopic Dermatitis Patients
To understand the pharmacological significance of IL-13 degra-
dation byMMP-8, we assessed the level of MMP-8 expression in
diseases where the pathology is driven by IL-13 overexpression.
To this end, we profiled serum MMP-8 levels in a cohort of pa-
tients with moderate to severe atopic dermatitis (n = 196) and
healthy age-matched controls (n = 30). Patients with atopic
dermatitis were found to have significantly lower levels of
circulating MMP-8 than healthy controls, as shown in Figure 5,
with geometric means of 1.2 3 105 and 2.98 3 105 pg/ml,
respectively.Chemistry & Biology 22, 1442–145DISCUSSION
Exploration of SubstratePromiscuity Reveals Previously
Unknown Catalytic Potential of Existing Proteases
We recorded the results of more than 500 protease/substrate
combinations, of which 5% resulted in reactions that could be
described as site specific and that occurred with a measurable
rate of catalysis. As expected, we confirmed that stable, globular
proteins are generally resistant to proteolysis (Fontana et al.,
1986, 1997), and that proteolytic attack is limited to areas of
disorder in protein structure (Fontana et al., 2004, 2012). Our
data further suggest that discovery of novel protease/substrate
combinations may be performed by surveying structures of
therapeutic targets for segments with elevated B factors, sol-
vent-exposed loops, or other areas of flexibility, and comparing
the sequence with known protease recognition motifs. The idea
that flexibility, exposure, and local interactions are parameters
influencing limited proteolysis of native proteins has been re-
ported previously (Hubbard, 1998), and the importance of these
structural features has recently been ranked (Kazanov et al.,
2011). However, the prediction of human protease specificity
has only been applied to limited systems such as the human pro-
teasome (Nussbaum et al., 2001), calpain (Liu et al., 2011),
caspases, and granzymes (Wang et al., 2014). An attempt at
generate a more global approach is described with PROSPER,
but is still limited to a few proteases of each class (Song et al.,
2012). Hence, with the availability of protease cleavage predic-
tion software relatively limited, our empirical approach to identi-
fying proteolytic events complements such in silico exploration,
and we report a number of previously unknown protease speci-
ficities. Moreover, all of the aforementioned approaches focus
only on proteolytic events, without assessing any functional con-
sequences on protein activity. One such observation led to the
discovery of specific and neutralizing enzymes, providing us
with a potentially therapeutic set of human proteases, MMPs,
and a therapeutic target susceptible to these proteases, IL-13.
Prospects of Promiscuous Activities for Therapeutic
Applications
MMPs are primarily degrading many components of the ECM
and basement membrane such as collagen, gelatin, fibronectin,
fibrin, and laminin, as they are involved in tissue remodeling and
maintenance. Recent degradomics studies suggest that MMPs
may also be involved in the regulation of the release or activation2, November 19, 2015 ª2015 Elsevier Ltd All rights reserved 1447
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Figure 4. Hydrolysis of IL-13 by MMPs in BAL of Humanized IL-
13 Mice
1 mM MMP-1, -8, 12, -20, or PBS were incubated for 24 hr at 37C in oval-
bumin-challenged mice expressing human IL-13. Levels of IL-13 were
measured by sandwich ELISA. Data shown are means ± SD in duplicate and
measured at the same time.
Figure 5. MMP-8 Expression in Patients with Moderate to Severe
Atopic Dermatitis and Normal Healthy Controls
The serum level of MMP-8 was measured using the Luminex platform. Each
point represents a single atopic dermatitis patient (n = 196) or healthy control
(n = 30). Geometric mean and 95% confidence interval are shown. ****P %
0.0001.of a number of bioactive molecules, and thus participate in
physiological processes such as innate and adaptive immu-
nity, inflammation, angiogenesis, bone remodeling, and neural
growth (Rodrı´guez et al., 2010). TopFIND, a database that main-
tains protease processing data (Fortelny et al., 2015), lists
IGFBP-1 (Lee et al., 2008), MIP-1a (Quintero et al., 2010), angio-
tensin, and substance P (Diekmann and Tschesche, 1994), and a
range of chemokines of the CCL and CXCL family (Starr et al.,
2012; Van Den Steen et al., 2003) as MMP-8 substrates. How-
ever, these degradomics studies are often limited to identifying
only novel cleavage points. In this study, we provide evidence
that cleavage alonemay not be sufficient for pharmacological ef-
fect, since potent target neutralization is only observed for the
degradation of IL-13 by MMP-8. To develop MMP-8 as a poten-
tial therapeutic inhibitor of IL-13, it will be necessary to assess
whether any of the other reported cleavage activities of MMP-8
can be reproduced and, more importantly, are of functional sig-
nificance. Similarly, MMP-20 has been reported to have broad
substrate specificity on peptide libraries (Turk et al., 2006), and
a similar effort would be warranted to confirm whether its pro-
miscuity has any additional functional relevance.
Further Elaboration of Protease Starting Points by
Protein Engineering
Given their potent neutralization of IL-13 and relative speci-
ficity, the new MMP activities reported here constitute starting
points for further engineering, overcoming the many limitations
of de novo design. MMP-8 is able to cleave a range of different
substrates such as fibrin, whose non-regulated cleavage due
to administration of therapeutic doses of MMP-8 could lead
to impaired clotting (Hiller et al., 2000). Also, overexpression
of MMP-8 impairs wound healing in mice (Gajendrareddy
et al., 2013) and is involved in airway destruction in bronchiec-
tasis (Zheng et al., 2002). Therefore, limiting off-target effects
is a requirement to make MMP-8 therapeutic. Recent research
suggests that engineering MMPs specificity might be feasible:1448 Chemistry & Biology 22, 1442–1452, November 19, 2015 ª2015a quantitative analysis of the relation between substrate
specificity and sequence variability at the amino acid level,
along with structural insight, allowed identification of as few
as four residues in MMP-16 that, when mutated into the
equivalent residues in MMP-17, established the specificity of
MMP-17 in the MMP-16 scaffold (Ratnikov et al., 2014),
demonstrating the potential for fine-tuning the substrate spec-
ificity of MMPs.
The rapid rate of autolysis of MMP-8 could limit its therapeutic
application, but can also be addressed by protein engineering.
However, stability was determined under conditions where
autolysis was favored, such as carrier protein free buffer, which
may not reflect physiological conditions in a more heteroge-
neous mixture (Ellerbroek et al., 2001; Ra et al., 2009). Hence,
any stability engineering effort would be best directed by a pre-
cise understanding of MMP degradation and elimination path-
ways in vivo.
Finally, an MMP-based therapy will need to evade serum in-
hibitors. It has been shown that membrane-bound MMP-8 is
resistant to inhibition by TIMPs (Owen et al., 2004), which sug-
gests it may be possible to engineer MMP-8 such that inhibition
by TIMP is largely avoided. In addition, the low concentration at
which TIMPs are found in serum and tissues might also be insuf-
ficient to inhibit recombinant MMPs employed at therapeutic
doses. This is further substantiated by our data demonstrating
IL-13 neutralization in BAL, which has been shown to contain sol-
uble protease inhibitors such as TIMPs (Erlewyn-Lajeunesse
et al., 2008). One therapeutically relevant MMP inhibitor we
have not examined in this study is a2-macroglobulin. This prote-
ase inhibitor functions as a ‘‘molecular trap’’ for proteases,
rapidly removing them from circulation with plasma levels in
the range of 2–4 mg/ml in humans (Sottrup-Jensen, 1989).
Many humanmetalloproteinases are inhibited by a2-macroglob-
ulin, including MMP-8, and avoiding inhibition by a2-macroglob-
ulin is likely to be a key consideration for the development of anyElsevier Ltd All rights reserved
proteasewhereby an extended duration of action is required. It is
important to note also that a2-macroglobulin is present in BAL,
and it is again possible that it is present in insufficient quantities
to inhibit recombinant MMP-8 at therapeutic doses.
Implications: A Role for Promiscuous Activities in
Biological Regulation and Disease?
This study raises the question as to whether the cleavage of
IL-13 by MMPs is relevant in vivo, akin to an underground
network of biological activities with evolutionary potential
(Notebaart et al., 2014). MMPs are typical promiscuous en-
zymes displaying different functions by cleaving a range of
substrates in different compartments with different activity
levels (Copley, 2015). Serum MMP-8 levels are suppressed
in atopic dermatitis (Figure 5), a disease known to be strongly
associated with IL-13 (Tazawa et al., 2004). Thus, the current
data suggest that the low expression of MMP-8 could lead to
impaired regulation of IL-13, contributing to disease patho-
genesis. MMP-8 polymorphisms have also been associated
with susceptibility to asthma (Shimoda et al., 2013) and peri-
odontitis (Gonzales et al., 2011). The neutralization of IL-13
by MMP-8 may therefore be of relevance in the pathogenesis
of a number of inflammatory diseases such as asthma, atopic
dermatitis, and periodontitis. Mice deficient in MMP-8 have
enhanced susceptibility to airway inflammation induced by
allergen (Gueders et al., 2005) and house mites (Chen et al.,
2008), further indicating that MMP-8 exerts an anti-inflamma-
tory role in asthma. Finally, MMP-8 plays a protective role
in asthmatic mice by cleaving membrane-bound IL13Ra-2
(Chen et al., 2008, 2009). The soluble form of IL13Ra-2 is
then able to sequester IL-13 with high affinity, preventing
downstream signaling. While IL13Ra-2 biology in humans
and mice is markedly different, with the soluble form of
IL13Ra-2 absent or only present at very low concentration in
human plasma samples (Chen et al., 2009; O’Toole et al.,
2008), these data further demonstrate the unique association
of MMP-8 and IL-13. This also highlights the need to increase
our understanding of mechanisms by which MMP-8 can con-
trol IL-13-driven human inflammatory disease.
SIGNIFICANCE
In thiswork, we show for the first time that the substrate pro-
miscuity of human proteases provides potent starting points
for protease-based therapeutics against relevant protein
targets. The discovery of IL-13 neutralization by human
MMPs, in particular MMP-8, fulfills all the basic require-
ments for therapeutic use and, at a minimum, constitutes a
reasonable starting point for future protease engineering ef-
forts. Backed by genetics and genomics data, we conclude
that our additional and novel observations of human prote-
ase promiscuity likely constitute an underground network
of biological signaling that has so far not been recognized
in disease pathology.
EXPERIMENTAL PROCEDURES
A list of reagents and mass spectrometry experiments is available in Supple-
mental Experimental Procedures.Chemistry & Biology 22, 1442–145Proteolysis Reactions for the Matrix
Reactions were carried out at 1–5 mM substrate and a 1:20 ratio of protease to
target, in either Dulbecco’s PBS (DPBS) (pH 7.4) or DPBS (pH 7.4) containing
1 mM CaCl2 and 20 mM ZnCl2, at 37
C. Aliquots containing 0.8–2 mg of target
were taken after 3 and 24 hr, stopped by the addition of NuPage sample
reducing agent and NuPage SDS sample loading buffer (Invitrogen), and incu-
bated at 70C for 10 min. Samples were loaded on NuPage Novex 4%–12%
Bis-Tris gels (Invitrogen) and run in 2-(N-morpholino)ethanesulfonic acid
buffer. Gels were visualized by silver staining using the SilverXpress kit
(Invitrogen).
Sample Preparation for the Bioassays
For MCP-1 and IL-13, proteolyzed samples were prepared by incubation of
5 mM target substrate with 250 nM MMP-8 in DPBS (pH 7.4) containing
1 mM CaCl2 and 20 mM ZnCl2 at 37
C for either 3 hr (MCP-1) or 24 hr (IL-
13). Reactions were stopped by the addition of 500 nM TIMP-1. Control
samples were prepared by first adding 500 nM TIMP-1 samples, followed by
addition of 250 nM MMP-8.
5 mM IL-6 was incubated with 1 mMKLK-7 in PBS at 37C. After 24 hr, serine
protease inhibitors PMSF and aprotinin were added at 1 mM and 10 mg/ml,
respectively. Control samples of IL-6were prepared as above with appropriate
inhibitors.
Additional control samples including samples containing either MCP-1, IL-
13, or IL-6 alone, as well as samples containing inhibitors alone, were also
prepared.
MCP-1 Bioassay: FLIPR
The FLIPR Ca2+ release bioassay (Sullivan et al., 1999) for processed MCP-1
was carried out as follows. THP-1 cells were spun down from culture me-
dium, resuspended in dye loading solution (RPMI-1640, 0.1% fetal calf
serum [FCS], 20 mM HEPES, 2.5 mM probenecid [Sigma], 0.03% pluronic
acid [Invitrogen], and 2 mM FLUO-4 AM [TEF Labs]), and incubated at
37C, 5% CO2 for 30 min. Cells were washed once in RPMI-1640, 0.1%
FCS, twice in FLIPR buffer (25 mM HEPES, 125 mM NaCl, 5 mM KCl,
1 mM MgCl2, 1.5 mM CaCl2, 2.5 mM probenecid, 1% FCS, and 0.5%
glucose), and resuspended at 4.3 3 106 cells/ml in FLIPR buffer. 70 ml of
cell suspension was aliquoted per well in 96-well black-wall tissue culture
plates, followed by centrifugation.
MCP-1 samples were diluted serially in V-bottom polypropylene plates.
The cell and sample plates were loaded in an FLIPR Tetra (Molecular De-
vices), and the experiment was initiated by the automated addition of 30 ml
of each sample to wells in the THP-1 cell plate. Peak fluorescence at each
MCP-1 concentration were fitted to four-parameter dose-response curves
to determine EC50s.
IL-13 and IL-6 Bioassays: TF1 Proliferation
The TF1 proliferation bioassay (Kitamura et al., 1989) for processed IL-13 and
IL-6 was carried out as follows. TF1 cells (R&D Systems) were washed three
times in culture media (RPMI-1640 Glutamax [Invitrogen], 5% heat-inactivated
fetal bovine serum, 1% sodium pyruvate [Sigma], 1% penicillin/streptomycin
[Invitrogen], and resuspended to a final concentration of 2 3 105 cells/ml in
the same culture media. 100 ml of cell suspension was dispensed into each
well of a 96-well, flat-bottomed plate, and 100 ml of IL-6 or IL-13 was added
to the wells over a defined titration range. Cells were cultured for 3 days at
37C, 5% CO2. Plates were then pulsed with 0.2 mCi/well of tritiated thymidine
(GE LifeSciences) for 4 hr at 37C, 5% CO2. Cells were harvested onto glass-
fiber filter plates and dried. 50 ml of scintillant (Microscint, PerkinElmer) was
dispensed onto each well of the filter plates, sealed, and thymidine incorpora-
tion determined using a liquid scintillation counter (Topcount, PerkinElmer),
and expressed as counts per minute.
Proteolysis for the Cleavage of IL-13 by MMPs
MMPs were sourced from Giotto Biotech, which were R95% pure, and for
which the folding state had been confirmed by NMR. Proteolysis reactions
were set up and analyzed by SDS-PAGE as described in Proteolysis Reactions
for the Matrix. MMP-3mut, MMP-10mut, and MMP-12mut were variants of the
corresponding MMPs containing the mutation F171D that was reported to
enhance solubility without affecting catalytic activity (Bertini et al., 2005).2, November 19, 2015 ª2015 Elsevier Ltd All rights reserved 1449
Hydrolysis of IL-13 in BAL
BAL samples from seven IL-13 humanized mice challenged with ovalbumin
(Sigma) as described previously (McMillan et al., 2002) were pooled. Proteol-
ysis reactions were set up in duplicates by adding 1 mMMMP to the BAL, and
incubated 24 hr at 37C. At the end of the incubation period, IL-13 levels were
measured using the human IL-13 Ultra-Sensitive Kit from Meso Scale
Discovery.
Stability of MMPs Catalytic Domains
Proteaseswere incubated at 100 nM in Tris-buffered saline (TBS), 1mMCaCl2,
100 mM ZnCl2 (pH 7.5) at 37
C, and aliquots were taken at regular intervals.
Residual activity was measured by following the hydrolysis of FRET peptide
substrates at 25C by following the appearance of Mca fluorescence at
lex = 325 nm and lem = 405 nm in a PerkinElmer EnVision fluorescence plate
reader. Samples were prepared in triplicates, at 1 and 10 nM enzyme using
5 mM Mca-KPLGL-Dpa-AR-NH2 (FS-6 substrate, R&D), except for MMP-3
whose activity was determined using 5 mM Mca-PLA-Nva-Dpa-AR-NH2
(Anaspec). The percentage of residual activity was plotted as a function of in-
cubation time, and half-lives were derived from one-phase decay curve fittings
with a plateau set at zero.
Kinetics of Hydrolysis of the Fluorogenic FS-6 Substrate
Hydrolysis of the peptide substrate FS-6 was monitored as above in 50 mM
TBS containing 1 mM CaCl2 and 100 mM ZnCl2. Time courses of hydrolysis
were measured for substrate concentrations of 0.5–10 mM and 1–5 nM
enzyme. Initial rates were determined from a linear fit to measured fluores-
cence during the linear phase of the reaction. Fluorescence rates were con-
verted to rates of product appearance from measurement of fluorescence
for known concentrations of the Mca reference standard Mca-Pro-Leu (Anas-
pec 27160). Plots of the initial rate data were linear at all concentrations of
enzyme and substrate, indicating that [S] < KM. Thus a second-order rate
kcat/KM was determined under subsaturating conditions from a linear fit of
the measured velocity data to the equation V = (kcat/KM)[E][S], describing the
behavior of the Michaelis-Menten equation for [S] < KM.
Kinetics of Hydrolysis of IL-13
Proteolysis reactions were set up in duplicate with 5 mM IL-13 and 250 nM
MMP in TBS containing 1 mMCaCl2, 100 mMZnCl2, and 0.1% BSA. At regular
intervals, aliquots were diluted 1:100 in TBS, BSA 0.1%, and 1 mM EDTA to
stop the reaction. For each time point, intact IL-13 concentration was
measured using the human IL-13 Ultra-Sensitive Kit from Meso Scale Discov-
ery. Plots of intact IL-13 concentration as a function of time were fit by a single
exponential. The value of kcat/KM was calculated from the half-life, as deter-
mined from fits to the time-dependent IL-13 clearance, using a form of the in-
tegrated rate equation kcat/KM = ln2/(t1/2.[E]) for the limiting behavior [S] < KM.
Kinetics of TIMPs Inhibition
TIMPs (0–100 nM) were incubated with 1 nM enzyme in TBS containing 1 mM
CaCl2 and 100 mM ZnCl2 for 1 hr at room temperature, before adding 1 mM
FS-6 substrate. Hydrolysis of FS-6 was monitored as above, and initial rates
were determined from a linear fit to measured product fluorescence. Ki(app)
was calculated from the equation v0/vi = 1+[I0]/Ki(app) by plotting (v0/vi)  1
against [I0], which gives a slope of 1/Ki(app).
Serum Measurements of MMP-8
Patients
Serum samples from 196 patients with atopic dermatitis as defined by the
criteria of Hanifin and Rajka (1980) were obtained. All patients had given prior
consent for use of biological samples in future studies in accordance with
applicable laws and regulations. Age- and sex-matched serum samples
from healthy controls (n = 30) were also obtained.
Luminex Measurement of MMP-8
MMP-8 was measured in the serum of atopic dermatitis patients using the Lu-
minex platform. Multiplex immunoassays were performed at the MultiPlex
Core Facility of the Laboratory for Translational Immunology (UMC Utrecht,
the Netherlands) using an in-house validated methodology. Uniquely color-
coded magnetic beads (MagPlex Microspheres; Luminex) were conjugated
to antibodies specific for MMP-8 and incubated with 50 ml of standard dilutions1450 Chemistry & Biology 22, 1442–1452, November 19, 2015 ª2015or sample for 1 hr (continuous shaking in the dark). Pre-treatment of samples
included filtration and incubation with HeteroBlock to prevent interference by
binding of heterophilic antibodies. Plates were washed (Bio-Plex Pro II Wash
Station; Bio-Rad) and a biotinylated detection antibody was added for 1 hr.
Repeated washings were followed by a 10-min streptavidin-phycoerythrin
(PE) incubation. Fluorescence intensity of PE was measured using a Flexmap
3D system (Luminex) and analyzed using BioPlex Manager software (version
6.1; Bio-Rad) using five-parameter curve fitting.
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